NOS2 and breast cancer: Given that inflammation is commonly encountered in breast cancers, the poor prognosis predicted by increased tumor expression of NOS2 and/or COX2 may in part be due to an altered tumor immune microenvironment that limits treatment efficacy and clinical outcome.